Seal Quality QRM for Medical Device Packaging: The Complete Strategy
An effective quality risk management (QRM) strategy for medical device pouch seals rests on four decisions: target the seal, not a generic pinhole number; size the defect threshold to the seal's actual geometry; replace manual visual inspection with a method that can see what visual inspection can't; and deploy that method on 100% of units, not a sample. Get these four right, and the resulting program also satisfies what FDA's Quality Management System Regulation (QMSR) now expects of a documented, risk-based quality system.
Why should medical device pouch QRM focus on the seal?
Recall data settles this question. An analysis of the FDA Recall Dashboard covering January 2019 through January 2025 identified 791 seal-integrity-related recalls, 74.8% of them in pouches and bags, and 96.7% affecting medical devices rather than drugs or biologics. Nearly all of it traced to seal formation, not a discrete puncture.
What's the right target defect size?
Decades of critical-defect-size literature were built on pinhole studies, not seal channels — and a pinhole and a channel of the same nominal width don't flow gas at the same rate. Applying real seal geometry (6mm or wider for Class III devices) to the flow physics pushes the defensible risk threshold well above the inherited pinhole number.
Why can't manual visual inspection carry this program?
Published reliability figures for visual inspection range from 60% to nearly 100% depending on inspector and conditions, and validation studies of the method are themselves distorted by the Hawthorne effect. Several of the seal defects that matter most — weak seals, incomplete seals — don't look different from a good seal to the human eye.
What inspection technology closes the gap?
Airborne ultrasound (ABUS) measures the seal's acoustic signature directly, non-destructively, at production speed, on every unit — including opaque and porous materials like Tyvek that few other non-destructive methods can characterize. It is recognized in ASTM F3004 and ISO 11607.
How does this align with QMSR and ISO 13485?
Since February 2, 2026, FDA's Quality Management System Regulation incorporates ISO 13485:2016 by reference and inspects quality systems on a risk basis rather than a fixed checklist. A seal-integrity program built on a manufacturer's own recall and complaint evidence, sized to its own geometry, and inspected at 100% is precisely the documented, product-specific risk management QMSR was written to encourage.
The critical path: (1) mine your own recall and complaint data for seal-defect patterns; (2) recalculate your target defect size against your actual seal width and material; (3) audit whether visual inspection is quietly carrying risk it can't detect; (4) pilot 100% automated seal inspection on your highest-risk line; (5) document the whole chain as your QMSR risk management record.